http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015190467-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0314922efadd540a40d70ff927be180f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0381 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate | 2013-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c9a0bc4927ad90342c237c7601c4f65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dff268992fc1d5a8fddbacb352bc6673 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb8798e612cae73f09c8835277257455 |
| publicationDate | 2015-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2015190467-A1 |
| titleOfInvention | The use of ret agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a ret agonist kit |
| abstract | The present disclosure relates to the use of RET, a transmembrane tyrosine kinase receptor, agonist molecules for Haematopoietic Stem Cell (HSC) expansion protocols and HSC transplantation therapy. n RET signaling molecules are expressed by HSCs and Ret ablation leads to reduced HSC numbers. RET signals provide HSCs with critical Bcl2 and Bcl211 surviving cues, downstream of p38/MAP kinase and CREB activation. Accordingly, enforced expression of RET down-stream targets, Bcl2 or Bcl211, is sufficient to restore the activity of Ret null progenitors in vivo. Remarkably, activation of RET improves HSC survival or maintenance and in vivo transplantation efficiency, thus opening new horizons to the usage of RET agonist in HSC expansion and transplantation protocols. n Additionally, the present disclosure describes a kit comprising RET agonist molecules, to be used in HSC expansion protocols and transplantation therapy. |
| priorityDate | 2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.